Prescription under medical supervision

Therapeutic action

– Sulfone antibacterial, antileprotic


– Prophylaxis of toxoplasmosis and pneumocystosis, in combination with pyrimethamine and folinic acid
– Treatment of pneumocystosis, in combination with trimethoprim
– Paucibacillary and multibacillary leprosy, in combination with rifampicin and clofazimine

Forms and strengths

– 25 mg and 50 mg tablets and 100 mg scored tablets


– Prophylaxis of pneumocystosis only
Child: 2 mg/kg once daily (max. 100 mg daily)
Adult: 100 mg once daily

– Prophylaxis of toxoplasmosis and pneumocystosis
Child: 2 mg/kg once daily (max. 25 mg daily)
Adult: 200 mg once weekly or 50 mg once daily

– Treatment of pneumocystosis
Child: 2 mg/kg once daily (max. 100 mg daily)
Adult: 100 mg once daily

– Paucibacillary and multibacillary leprosy
Child under 10 years: 2 mg/kg once daily
Child from 10 to 14 years: 50 mg once daily
Child 15 years and over and adult: 100 mg once daily


– Prophylaxis of toxoplasmosis and pneumocystosis: as long as necessary; treatment of pneumocystosis: 21 days; paucibacillary leprosy: 6 months; multibacillary leprosy: 12 months

Contra-indications, adverse effects, precautions

– Do not administer to patients with allergy to sulfones or severe anaemia (first treat anaemia).
– Administer with caution to patients with renal or hepatic impairment.
– May cause: haemolytic anaemia in patients with G6PD deficiency, dose-related haemolytic anaemia, neutropenia, methaemoglobinaemia, pruritus, rash, gastrointestinal disturbances, peripheral neuropathies, agranulocytosis; hypersensitivity reactions during the first month of treatment (fever, jaundice, hepatitis, adenopathy, exfoliative dermatitis, etc.) requiring permanent discontinuation of treatment.
– Monitor blood count and transaminases if possible.
– Monitor combination with zidovudine (increased haematological toxicity).
– Pregnancy: no contra-indication
– Breast-feeding: no contra-indication


  Storage: below 25 °C  -